Health Care • Medical/Dental Instruments
$4.08 ▼ -0.02
(-0.49%)
MKT CAP: $281.4M • VOL: 1.23M
52W L $2 52W H $5
OSUR // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $115.0M | $185.8M | $405.5M |
| YoY Revenue Growth % | -38.1% | -54.2% | — |
| Gross Profit | $48.2M | $79.4M | — |
| Gross Margin % | 41.9% | 42.7% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$72.0M | -$28.3M | $32.7M |
| Operating Margin % | -62.6% | -15.2% | 8.1% |
| Net Income (GAAP) | -$68.7M | -$19.5M | $53.7M |
| EBITDA (Normalized) | -$68.6M | -$25.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$49.0M | $27.4M | $141.6M |
| Capital Expenditures (CapEx) | $4.2M | $3.8M | — |
| Free Cash Flow (FCF) | -$53.2M | $23.6M | $141.6M |
| FCF Margin % | -46.3% | 12.7% | 34.9% |
| Return on Invested Capital (ROIC %) | -40.2% | -15.7% | — |
| Cash & Short-Term Equivalents | $199.3M | $267.8M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $340.8M | $410.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR OSUR.